Abstract
The use of absorption promoters is a way to improve the bioavailability and therapeutic response of topically applied ophthalmic drugs. The ocular tolerance of 9 potential absorption promoters was investigated as well as the influence of the enhancers' concentration on the ocular tolerance. The substances tested were instillated repetitively (4 times per day, during 3 days, and once just before examination) as aqueous solutions onto rabbit corneas. Fluorescein dyeing enabled us to specifically mark corneal damage that was observed by confocal microscopy. The degree of corneal injury was assessed with an image-processing system that calculated the total fluorescent areas. Confocal microscopy results showed the relatively good tolerance of permeation enhancers like dimethyl sulfoxide (DMSO), decamethonium, edetate, glycocholate, and cholate in contrast to the poorly tolerated saponin and fusidate. Increasing the promoters' concentration led generally to an increase in corneal lesions.
Keywords: ocular absorption, permeation enhancers, confocal microscopy, toxicity
References
- 1.Lee VHL, Robinson JR. Review: topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986;2:67–108. doi: 10.1089/jop.1986.2.67. [DOI] [PubMed] [Google Scholar]
- 2.Liaw J, Robinson JR. Ocular penetration enhancers. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York, NY: Marcel Dekker; 1993. pp. 369–381. [Google Scholar]
- 3.Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999;16:85–146. [PubMed] [Google Scholar]
- 4.Sasaki H, Igarashi Y, Nagano T, Nishida K, Nakamura J. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res. 1995;12:1146–1150. doi: 10.1023/A:1016203725128. [DOI] [PubMed] [Google Scholar]
- 5.Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release. 1994;29:253–267. doi: 10.1016/0168-3659(94)90072-8. [DOI] [Google Scholar]
- 6.Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol. 1995;47:703–707. doi: 10.1111/j.2042-7158.1995.tb06726.x. [DOI] [PubMed] [Google Scholar]
- 7.Sasaki H, Tei C, Yamamura K, Nishida K, Nakamura J. Effect of preservatives on systemic delivery of insulin by ocular instillation in rabbits. J Pharm Pharmacol. 1994;46:871–875. doi: 10.1111/j.2042-7158.1994.tb05705.x. [DOI] [PubMed] [Google Scholar]
- 8.Sasaki H, Tei C, Nishida K, Nakamura J. Effect of ophthalmic preservatives on serum concentration and local irritation of ocularly applied insulin. Biol Pharm Bull. 1995;18:169–171. doi: 10.1248/bpb.18.169. [DOI] [PubMed] [Google Scholar]
- 9.Morgan RV. Delivery of systemic regular insulin via the ocular route in cats. J Ocul Pharmacol. 1995;11:565–573. doi: 10.1089/jop.1995.11.565. [DOI] [PubMed] [Google Scholar]
- 10.Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four?-blockers, and in vitro/in vivo toxic activity. Int J Pharm. 1996;142:103–113. doi: 10.1016/0378-5173(96)04663-7. [DOI] [Google Scholar]
- 11.Ismail IM, Chen CC, Richman JB, Andersen JS, Tang-Liu DDS. Comparison of azone and hexamethylene lauramide in toxicologic effects and penetration enhancement of cimetidine in rabbit eyes. Pharm Res. 1992;9:817–821. doi: 10.1023/A:1015820009255. [DOI] [PubMed] [Google Scholar]
- 12.Durand-Cavagna G, Duprat P, Molon-Noblot S, Delort P, Rozier A. Corneal endothelial changes with azone, a penetration enhancer. In: Lerman S, Tripathi RC, editors. Ocular Toxicology. New York, NY: Marcel Dekker; 1988. pp. 109–117. [PubMed] [Google Scholar]
- 13.Rojanasakul Y, Liaw J, Robinson JR. Mechanisms of action of some penetration enhancers in the cornea: laser microscopic and electrophysiology studies. Int J Pharm. 1990;66:131–142. doi: 10.1016/0378-5173(90)90392-H. [DOI] [Google Scholar]
- 14.Furrer P, Mayer JM, Gurny R. Confocal microscopy as a tool for the investigation of the anterior part of the eye. J Ocular Pharmacol. 1997;13:559–578. doi: 10.1089/jop.1997.13.559. [DOI] [PubMed] [Google Scholar]
- 15.ARVO Statement for the use of animals in ophthalmic and vision research. Invest Ophthalmol Vis Sci. 1994;35:v–vi. [Google Scholar]
- 16.Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm. 1999;180:185–193. doi: 10.1016/S0378-5173(99)00003-4. [DOI] [PubMed] [Google Scholar]
- 17.Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm. 2000;207:89–98. doi: 10.1016/S0378-5173(00)00540-8. [DOI] [PubMed] [Google Scholar]
- 18.Chiou GCY, Chuang CY. Improvement of systemic absorption of insulin through eyes with absorption enhancers. J Pharm Sci. 1989;78:815–818. doi: 10.1002/jps.2600781007. [DOI] [PubMed] [Google Scholar]
- 19.Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett. 2001;122:1–8. doi: 10.1016/S0378-4274(01)00261-2. [DOI] [PubMed] [Google Scholar]
- 20.Norn MS. Micropunctate fluorescein vital staining of the cornea. Acta Ophthalmol. 1970;48:99–109. doi: 10.1111/j.1755-3768.1970.tb06578.x. [DOI] [PubMed] [Google Scholar]
- 21.Tabery HM. Micropunctate fluorescein staining of the human corneal surface: microerosion or cystic spaces? Acta Ophthalmol Scand. 1997;75:134–136. doi: 10.1111/j.1600-0420.1997.tb00108.x. [DOI] [PubMed] [Google Scholar]